ARCH Venture Management as of June 30, 2026
Portfolio Holdings for ARCH Venture Management
ARCH Venture Management holds 12 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Parabilis Medicines | 16.0 | $176M | 6.4M | 27.37 | |
| Beam Therapeutics (BEAM) | 14.2 | $156M | 4.5M | 34.31 | |
| Rapport Therapeutics (RAPP) | 14.1 | $155M | 3.7M | 41.67 | |
| Seaport Therapeutics Common Stock | 12.4 | $137M | 6.3M | 21.70 | |
| Erasca (ERAS) | 11.8 | $130M | 7.1M | 18.32 | |
| Vir Biotechnology (VIR) | 11.8 | $129M | 13M | 10.19 | |
| Maze Therapeatics (MAZE) | 11.2 | $123M | 4.1M | 29.85 | |
| Lyell Immunopharma Com New (LYEL) | 4.1 | $46M | 3.2M | 14.02 | |
| Generate Biomedicines Com Shs (GENB) | 3.0 | $33M | 1.9M | 16.87 | |
| 10x Genomics Cl A Com (TXG) | 0.8 | $8.4M | 218k | 38.34 | |
| Boundless Bio (BOLD) | 0.6 | $6.7M | 2.7M | 2.50 | |
| Gossamer Bio (GOSS) | 0.1 | $1.3M | 8.1M | 0.16 |
